CD38 and Miyoshi myopathy: Previous studies have proven the aptamer–miRNA conjugates apt69.T-miRNA-137 and apt69.T-anti-miR-222 targeting BCMA and the aptamer–drug conjugate #1S-DOX targeting CD38 significantly inhibit MM cell activity, showing promise as emerging drugs to treat MM.